OPTIMIS: An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).
Markus Peck-Radosavljevic
Consultant or Advisory Role - Bayer Schering Pharma
Honoraria - Bayer Schering Pharma
Research Funding - Bayer Schering Pharma
Jean-Luc Raoul
Consultant or Advisory Role - Bayer Schering Pharma
Honoraria - Bayer Schering Pharma
Han Chu Lee
Research Funding - Bayer
Masatoshi Kudo
No relevant relationships to disclose
Keiko Nakajima
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Ann-Lii Cheng
Consultant or Advisory Role - Boehringer Ingelheim